|
20 Dec 2022 |
Kira Pharmaceuticals Announces Clearance to Initiate Phase 2 Evaluation of KP104 in IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G) in China and Australia
|
|
20 Dec 2022 |
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
|
|
20 Dec 2022 |
Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Uro
|
|
20 Dec 2022 |
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
|
|
19 Dec 2022 |
Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008
|
|
19 Dec 2022 |
Update on PEARL Phase III trial of Imfinzi monotherapy in Stage IV non-small cell lung cancer
|
|
19 Dec 2022 |
Enhertu approved in the EU for patients with previously treated HER2-positive advanced gastric cancer
|
|
17 Dec 2022 |
TG ImmunoPharma (TGI) announces FDA clearance of IND application for TGI-2, a novel anti-PVRIG therapeutic antibody
|
|
16 Dec 2022 |
Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer
|
|
16 Dec 2022 |
Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers
|
|
16 Dec 2022 |
Zhejiang Doer Biologics Announces Clinical Trial Collaboration with MSD to Evaluate DR30303 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Gastric or Gastroesophageal Junction Cancer
|
|
16 Dec 2022 |
Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022
|
|
16 Dec 2022 |
Blincyto® (blinatumomab) added to consolidation chemotherapy significantly improves survival in adult patients with measurable residual disease-negative B-lineage Acute Lymphoblastic Leukemia (B-ALL)
|
|
15 Dec 2022 |
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis
|
|
15 Dec 2022 |
Calypso Biotech Announces First Patient with Eosinophilic Esophagitis Dosed in Anti-Interleukin-15 (IL-15) Monoclonal Antibody CALY-002 Phase 1a/b Trial, and Animal Proof of Concept Data in Atopic Dermatitis
|
|
15 Dec 2022 |
Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects
|
|
14 Dec 2022 |
European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares
|
|
14 Dec 2022 |
Fresenius Kabi receives U.S. FDA approval for biosimilar Idacio® (adalimumab)
|
|
13 Dec 2022 |
Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial
|
|
12 Dec 2022 |
Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma
|
|
12 Dec 2022 |
Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting
|
|
12 Dec 2022 |
Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022
|
|
12 Dec 2022 |
Genentech Presents New Data Demonstrating the Potential of Glofitamab and Mosunetuzumab as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma
|
|
12 Dec 2022 |
Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio
|
|
12 Dec 2022 |
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas
|
